Protagonist Therapeutics Stock Current Liabilities
PTGX Stock | USD 31.94 2.33 7.87% |
Protagonist Therapeutics fundamentals help investors to digest information that contributes to Protagonist Therapeutics' financial success or failures. It also enables traders to predict the movement of Protagonist Stock. The fundamental analysis module provides a way to measure Protagonist Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protagonist Therapeutics stock.
Total Current Liabilities is likely to rise to about 27.7 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 209.9 K in 2024. Protagonist | Current Liabilities |
Protagonist Therapeutics Company Current Liabilities Analysis
Protagonist Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Protagonist Therapeutics Current Liabilities | 6.43 M |
Most of Protagonist Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protagonist Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protagonist Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagonist Therapeutics is extremely important. It helps to project a fair market value of Protagonist Stock properly, considering its historical fundamentals such as Current Liabilities. Since Protagonist Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagonist Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagonist Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Protagonist Current Liabilities Historical Pattern
Today, most investors in Protagonist Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Protagonist Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Protagonist Therapeutics current liabilities as a starting point in their analysis.
Protagonist Therapeutics Current Liabilities |
Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
Protagonist Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Protagonist Therapeutics has a Current Liabilities of 6.43 M. This is 99.63% lower than that of the Biotechnology sector and 98.82% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.92% higher than that of the company.
Protagonist Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagonist Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagonist Therapeutics could also be used in its relative valuation, which is a method of valuing Protagonist Therapeutics by comparing valuation metrics of similar companies.Protagonist Therapeutics is currently under evaluation in current liabilities category among related companies.
Protagonist Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protagonist Therapeutics from analyzing Protagonist Therapeutics' financial statements. These drivers represent accounts that assess Protagonist Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protagonist Therapeutics' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 182.6M | 693.4M | 1.6B | 535.1M | 1.3B | 1.4B | |
Enterprise Value | 166.6M | 582.0M | 1.5B | 413.0M | 1.1B | 1.2B |
Protagonist Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protagonist Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protagonist Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Protagonist Fundamentals
Return On Equity | 0.42 | ||||
Return On Asset | 0.21 | ||||
Profit Margin | 0.51 % | ||||
Operating Margin | 0.81 % | ||||
Current Valuation | 1.33 B | ||||
Shares Outstanding | 58.65 M | ||||
Shares Owned By Insiders | 1.24 % | ||||
Shares Owned By Institutions | 98.76 % | ||||
Number Of Shares Shorted | 3.73 M | ||||
Price To Earning | (4.81) X | ||||
Price To Book | 4.68 X | ||||
Price To Sales | 26.26 X | ||||
Revenue | 60 M | ||||
Gross Profit | 26.58 M | ||||
EBITDA | (90.34 M) | ||||
Net Income | (78.95 M) | ||||
Cash And Equivalents | 291.89 M | ||||
Cash Per Share | 5.95 X | ||||
Total Debt | 1.14 M | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 7.59 X | ||||
Book Value Per Share | 9.56 X | ||||
Cash Flow From Operations | (70.24 M) | ||||
Short Ratio | 6.86 X | ||||
Earnings Per Share | 2.54 X | ||||
Target Price | 44.8 | ||||
Number Of Employees | 124 | ||||
Beta | 2.08 | ||||
Market Capitalization | 1.66 B | ||||
Total Asset | 357.95 M | ||||
Retained Earnings | (615.71 M) | ||||
Working Capital | 334.3 M | ||||
Current Asset | 83.24 M | ||||
Current Liabilities | 6.43 M | ||||
Net Asset | 357.95 M |
About Protagonist Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagonist Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagonist Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagonist Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Protagonist Therapeutics Investors Sentiment
The influence of Protagonist Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Protagonist. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Protagonist Therapeutics' public news can be used to forecast risks associated with an investment in Protagonist. The trend in average sentiment can be used to explain how an investor holding Protagonist can time the market purely based on public headlines and social activities around Protagonist Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Protagonist Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Protagonist Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Protagonist Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Protagonist Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagonist Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagonist Therapeutics' short interest history, or implied volatility extrapolated from Protagonist Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protagonist Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Protagonist Therapeutics Piotroski F Score and Protagonist Therapeutics Altman Z Score analysis. For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Protagonist Stock analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.54 | Revenue Per Share 5.308 | Quarterly Revenue Growth (1.00) | Return On Assets 0.2138 | Return On Equity 0.4175 |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.